ATIC are supporting recruitment for a clinical trial of a potential new treatment for type 1 diabetes called SAB-142. This immune-modifying treatment is expected to have similar benefits to thymoglobulin, an ATG treatment which is TGA approved for organ transplant recipients, without unwanted side-effects.

Participants in the trial will be required to attend a 7-night/8-day admission to the clinical trial centre located in Bayswater, Victoria. Followed by six trial visits over four months.

Participants will be compensated for their time.